InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,714.10
(
-0.26%
)
US TECH 100
19,475.60
(
-0.11%
)
Dow Jones
41,802.65
(
-0.59%
)
Brent Oil
75.18
(
1.48%
)
Bitcoin
67,502.69
(
-1.80%
)
Post# of 253525
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120662
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 237490

Friday, 11/19/2021 9:12:12 AM

Friday, November 19, 2021 9:12:12 AM

Post# of 253525
BMY—Mavacamten PDUFA extended 3mo to 4/28/22:

https://www.businesswire.com/news/home/20211119005267/en

The FDA simply needs more time to complete the NDA review—it has not requested any new data or analyses from BMY.

Mavacamten is the drug BMY got in the $13.1B acquisition of MYOK in Oct 2020 (#msg-158698900).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up